OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months
Jennifer Serwanga, Violet Ankunda, Jackson Sembera, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Jennifer Serwanga, Violet Ankunda, Jackson Sembera, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Showing 16 citing articles:
Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort
Gerald Kevin Oluka, Jackson Sembera, Joseph Ssebwana Katende, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 143-143
Open Access | Times Cited: 1
Gerald Kevin Oluka, Jackson Sembera, Joseph Ssebwana Katende, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 143-143
Open Access | Times Cited: 1
Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study
Houda Amellal, Najlaa Assaid, Hicham Charoute, et al.
PLoS ONE (2023) Vol. 18, Iss. 7, pp. e0288557-e0288557
Open Access | Times Cited: 16
Houda Amellal, Najlaa Assaid, Hicham Charoute, et al.
PLoS ONE (2023) Vol. 18, Iss. 7, pp. e0288557-e0288557
Open Access | Times Cited: 16
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy
Jennifer Serwanga, Claire Baine, Susan Mugaba, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Jennifer Serwanga, Claire Baine, Susan Mugaba, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Sustained S-IgG and S-IgA antibodies to Moderna’s mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations
Jennifer Serwanga, Violet Ankunda, Joseph Ssebwana Katende, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Jennifer Serwanga, Violet Ankunda, Joseph Ssebwana Katende, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies
Violet Ankunda, Joseph Ssebwana Katende, Gerald Kevin Oluka, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Violet Ankunda, Joseph Ssebwana Katende, Gerald Kevin Oluka, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Performance of SARS COV-2 IgG Anti-N as an Independent Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population
Adam Abdullahi, James Opoku Frimpong, Mark T. K. Cheng, et al.
American Journal of Tropical Medicine and Hygiene (2023) Vol. 109, Iss. 4, pp. 890-894
Open Access | Times Cited: 6
Adam Abdullahi, James Opoku Frimpong, Mark T. K. Cheng, et al.
American Journal of Tropical Medicine and Hygiene (2023) Vol. 109, Iss. 4, pp. 890-894
Open Access | Times Cited: 6
Spike protein is a key target for stronger and more persistent T-cell responses—a study of mild and asymptomatic SARS-CoV-2 infection
Ivan Ssali, Susan Mugaba, Arthur Kalyebi Watelo, et al.
International Journal of Infectious Diseases (2023) Vol. 136, pp. 49-56
Open Access | Times Cited: 5
Ivan Ssali, Susan Mugaba, Arthur Kalyebi Watelo, et al.
International Journal of Infectious Diseases (2023) Vol. 136, pp. 49-56
Open Access | Times Cited: 5
Sustained spike-specific IgG antibodies following CoronaVac (Sinovac) vaccination in sub-Saharan Africa, but increased breakthrough infections in baseline spike-naive individuals
Jackson Sembera, Claire Baine, Violet Ankunda, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Jackson Sembera, Claire Baine, Violet Ankunda, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
An Optimised Indirect ELISA Protocol for Detection and Quantification of Anti-viral Antibodies in Human Plasma or Serum: A Case Study Using SARS-CoV-2
Claire Baine, Jackson Sembera, Gerald Kevin Oluka, et al.
BIO-PROTOCOL (2023) Vol. 13, Iss. 24
Open Access | Times Cited: 5
Claire Baine, Jackson Sembera, Gerald Kevin Oluka, et al.
BIO-PROTOCOL (2023) Vol. 13, Iss. 24
Open Access | Times Cited: 5
The Single-Dose Janssen Ad26.COV2.S COVID-19 Vaccine Elicited Robust and Persistent Anti-Spike IgG Antibody Responses in A 12-Month Ugandan Cohort
Jennifer Serwanga, Laban Kato, Violet Ankunda, et al.
(2024)
Open Access | Times Cited: 1
Jennifer Serwanga, Laban Kato, Violet Ankunda, et al.
(2024)
Open Access | Times Cited: 1
Dynamics of SARS-CoV-2 antibodies after natural infection: insights from a study on Pasteur Institute of Tunis employees
Ines Cherif, Ghassen Kharroubi, Imen Darragi, et al.
Libyan Journal of Medicine (2024) Vol. 19, Iss. 1
Open Access
Ines Cherif, Ghassen Kharroubi, Imen Darragi, et al.
Libyan Journal of Medicine (2024) Vol. 19, Iss. 1
Open Access
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort
Jennifer Serwanga, Laban Kato, Gerald Kevin Oluka, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Jennifer Serwanga, Laban Kato, Gerald Kevin Oluka, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles
Jennifer Serwanga, Gerald Kevin Oluka, Claire Baine, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0303113-e0303113
Open Access
Jennifer Serwanga, Gerald Kevin Oluka, Claire Baine, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0303113-e0303113
Open Access
Genetic, Clinical, Epidemiological, and Immunological Profiling of IgG Response Duration after SARS-CoV-2 Infection
Flávia Póvoa da Costa, Kevin Matheus Lima de Sarges, Rosilene da Silva, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8740-8740
Open Access
Flávia Póvoa da Costa, Kevin Matheus Lima de Sarges, Rosilene da Silva, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8740-8740
Open Access
The Distinct Absence of a Post-boost Spike-IgG Antibody Surge in Ugandan Recipients of the Pfizer-BioNTech Vaccine Has Implications for Vaccination Policies
Jennifer Serwanga, Violet Ankunda, Joseph Ssebwana Katende, et al.
(2023)
Open Access | Times Cited: 1
Jennifer Serwanga, Violet Ankunda, Joseph Ssebwana Katende, et al.
(2023)
Open Access | Times Cited: 1
A novel highly specific biotinylated MAC-ELISA for detection of anti-SARS-CoV-2 nucleocapsid antigen IgM antibodies during the acute phase of COVID-19
Leonardo Lopes-Luz, Matheus Bernardes Torres Fogaça, Brenda Garcia Bentivoglio-Silva, et al.
Brazilian Journal of Microbiology (2023) Vol. 54, Iss. 4, pp. 2893-2901
Closed Access | Times Cited: 1
Leonardo Lopes-Luz, Matheus Bernardes Torres Fogaça, Brenda Garcia Bentivoglio-Silva, et al.
Brazilian Journal of Microbiology (2023) Vol. 54, Iss. 4, pp. 2893-2901
Closed Access | Times Cited: 1
